drugset / Trial / NCT00756249
Safety Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary purpose of the study is to determine whether carbamylated erythropoietin (CEPO) is a safe treatment for patients who have suffered an acute ischemic stroke.
Timeline
- Start
- 2007-10
- Primary completion
- 2008-09
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lu AA24493 | Protein / enzyme biologic | 0.005 ug/kg | Intravenous |
| Subject | Lu AA24493 | Protein / enzyme biologic | 0.05 ug/kg | Intravenous |
| Subject | Lu AA24493 | Protein / enzyme biologic | 0.5 ug/kg | Intravenous |
| Subject | Lu AA24493 | Protein / enzyme biologic | 5 ug/kg | Intravenous |
| Subject | Lu AA24493 | Protein / enzyme biologic | 50 ug/kg | Intravenous |